EI
NTLA icon

EAM Investors’s Intellia Therapeutics NTLA Stock Holding History

EAM Investors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,682
Closed -$2.37M – 345
2021
Q3 		$2.37M Sell
17,682
-4,064
-19% -$615K 0.4% 78
2021
Q2 		$3.52M Buy
+21,746
New +$1.69M 0.54% 37

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM Investors's NTLA Position: Q4 2021 in Review

EAM Investors sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 17,682 shares — an estimated $2.37M sold.

EAM Investors first reported a position in NTLA in Q2 2021 and held it in 2 quarters. The position peaked at $3.52M in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • EAM Investors reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • EAM Investors sold 17,682 Intellia Therapeutics shares in Q4 2021, an estimated $2.37M.
  • EAM Investors first reported a position in Intellia Therapeutics in Q2 2021 and held it in 2 quarters.
  • EAM Investors's Intellia Therapeutics position peaked at $3.52M in Q2 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on EAM Investors's 13F filing for Q4 2021, filed 11 Feb 2022.